Rather than effective measures, like lockdowns, quality masks, retrofitting buildings for minimum required ventilation, UV light filtration of indoor air... We got the neoliberal solution: A publicly financed, privately-owned medical product that doesn't stop transmission or pandemic/endemic disease in humans, but can be used as a bludgeon to get people back to work and stop caring.
I've talked about my clinical data background, proximity to the COVID vaccine programme in the past. I've always made sure to source everything well, as I've done for client sponsors whose COVID medical products are on the market (I did have a removed post in the modlog ~6 weeks back which had an interesting photo).
If a shot is outdated, not specific to the strain of the virus circulating most widely in humans, that's what it will do. As first observed by UK HSA in their vaccine surveillance report Week 42 (below): Inhibit your body’s ability to synthesize antibodies which are effective against the strain you were exposed to. That's just because of the philosophy of all vaccines produced and administered anywhere in the world thus far (mRNA, adenovirus, DNA, spike conjugated TT - whatever, doesn't matter) only have genetic material from the most rapidly mutating spike protein, subunit S1. The shots being administered until Omicron-specific boosters were produced imprinted the patient's immune system with a memory of the S1 protein isolated in Wuhan in 2019, despite the Delta strain being by far the most prominent at the time it was being recommended to everyone except children (or even required by OSHA for all employees working for firms with >100 employees).
Seropositivity estimates for N antibody will underestimate the proportion of the
population previously infected due to (i) blood donors are potentially less likely to be exposed to
natural infection than age matched individuals in the general population (ii) waning of the N
antibody response over time and (iii) recent observations from UK Health Security Agency
(UKHSA) surveillance data that N antibody levels appear to be lower in individuals who acquire
infection following 2 doses of vaccination.
When it comes to beta or alphacoronaviruses, there's always surveillance of spike protein (S) and nucleocapsid (N, also nucleoprotein) antibodies. It would have been obvious to regulators that this were a risk, since it's a coronavirus, but luckily really well done studies in Italy controlling for other factors found those with antibodies for endemic seasonal coronaviruses had worse outcomes from COVID-19 infections: https://pubmed.ncbi.nlm.nih.gov/33915711/
None of this is to suggest vaccines aren't useful, absolutely should have been recommended to the elderly or those at risk of severe illness or death, but for most younger or otherwise healthier people you'd be less likely to have repeat infections after surviving infection or waiting for an updated vaccine, ideally on a quality platform that accounts for genetic drift, without a previously imprinted immune response targeting a previous version of the virus. Research should have been primarily on long COVID after at least Oct 2021, so that we could make a real assessment.
Inhibiting your body's ability to synthesize proteins to own the libs.
Rather than effective measures, like lockdowns, quality masks, retrofitting buildings for minimum required ventilation, UV light filtration of indoor air... We got the neoliberal solution: A publicly financed, privately-owned medical product that doesn't stop transmission or pandemic/endemic disease in humans, but can be used as a bludgeon to get people back to work and stop caring.
I've talked about my clinical data background, proximity to the COVID vaccine programme in the past. I've always made sure to source everything well, as I've done for client sponsors whose COVID medical products are on the market (I did have a removed post in the modlog ~6 weeks back which had an interesting photo).
If a shot is outdated, not specific to the strain of the virus circulating most widely in humans, that's what it will do. As first observed by UK HSA in their vaccine surveillance report Week 42 (below): Inhibit your body’s ability to synthesize antibodies which are effective against the strain you were exposed to. That's just because of the philosophy of all vaccines produced and administered anywhere in the world thus far (mRNA, adenovirus, DNA, spike conjugated TT - whatever, doesn't matter) only have genetic material from the most rapidly mutating spike protein, subunit S1. The shots being administered until Omicron-specific boosters were produced imprinted the patient's immune system with a memory of the S1 protein isolated in Wuhan in 2019, despite the Delta strain being by far the most prominent at the time it was being recommended to everyone except children (or even required by OSHA for all employees working for firms with >100 employees).
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-report-week-42.pdf (page 23):
When it comes to beta or alphacoronaviruses, there's always surveillance of spike protein (S) and nucleocapsid (N, also nucleoprotein) antibodies. It would have been obvious to regulators that this were a risk, since it's a coronavirus, but luckily really well done studies in Italy controlling for other factors found those with antibodies for endemic seasonal coronaviruses had worse outcomes from COVID-19 infections: https://pubmed.ncbi.nlm.nih.gov/33915711/
None of this is to suggest vaccines aren't useful, absolutely should have been recommended to the elderly or those at risk of severe illness or death, but for most younger or otherwise healthier people you'd be less likely to have repeat infections after surviving infection or waiting for an updated vaccine, ideally on a quality platform that accounts for genetic drift, without a previously imprinted immune response targeting a previous version of the virus. Research should have been primarily on long COVID after at least Oct 2021, so that we could make a real assessment.